



S2Medical AB (publ) has signed an exclusive distribution agreement for Portugal

S2Medical AB (publ) has signed an exclusive distribution agreement for Portugal with Molecular Farma. The agreement covers all products that the company has in its portfolio, in the region, and with its initial order as well as obligations to place additional orders to a minimum of SEK 2 million over the next 3 years, this to honor the agreement.

“Our expectation is to quickly establish ourselves as a standard treatment in Portugal together with our new distributor as Epiprotect already is the standard treatment for burns in Sweden at both national burn units, in the U.K an additional 5 burn units and another 3 burn units in the United Arab Emirates.” says the company's CEO Petter Sivlér.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-09-2022 14:30 CET.

Kontaktuppgifter

Petter Sivlér – CEO, S2Medical AB (publ)

Telefon: +46 (0)8-70 000 50

E-post: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telefon +46 (0)8-580 065 99

Hemsida: www.vatorsec.se

Epost: ca@vatorsec.se

Om S2Medical

S2Medical AB (publ) är ett medicintekniskt bolag som utvecklar och säljer innovativa sårbehandlingsprodukter för hela sårbehandlingsprocessen med fokus på brännskador och kroniska sår. Bolaget har utvecklat eiratex®, ett nytt cellulosabaserat material för läkning av svåra brännskador och kroniska sår. Materialet läker sår effektivt och därmed minskar både lidande för patienter samt kostnader för hälso- och sjukvården.

Aktiens kortnamn: S2M

Aktiens ISIN-kod: SE0011725084